Thyroid Gland Carcinoma — Trials

Thyroid Gland Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

389 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 96
Recruiting: 39
Ph III recruiting: 5
Growth YoY: −15%
Industry share: 14%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 32.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (42)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04731740	Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer	withdrawn	Phase 2	0	Saint Petersburg State University, RussiaOTHER	1	Mar 25, 2024	clinicaltrials
NCT04739566	Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer(ANAPLAST-NEO)	withdrawn	Phase 2	0	Saint Petersburg State University, RussiaOTHER	1	Mar 25, 2024